Second Booster of COVID-19 Vaccines for the Prevention of COVID-19 Among Individuals Aged 50 Years Old and Older and Individuals with Comorbidities Aged 18 to 49 Years Old

Date of SOH Approval: 26 August 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of Second Booster of COVID-19 vaccines continue reading : Second Booster of COVID-19 Vaccines for the Prevention of COVID-19 Among Individuals Aged 50 Years Old and Older and Individuals with Comorbidities Aged 18 to 49 Years Old

Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus

Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here:  https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.) Document Preview:

Insulin detemir (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus

Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here:  https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.)

Eribulin for Metastatic Soft Tissue Sarcoma (mSTS)

Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF Document link: Evidence summary on eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via https://hta.doh.gov.ph/topic-nomination/.) Document Preview: